Paper · 29075855

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

van den Bent M and 23 others. Cancer Chemother Pharmacol, 2017. Cited by 111 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Papers, record 29075855. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29075855

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.; PubMed
Journal: Cancer Chemother Pharmacol; PubMed
Year: 2017; PubMed
Publication types: Clinical Trial, Phase I, Journal Article, Multicenter Study; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/29075855/; PubMed
DOI: https://doi.org/10.1007/s00280-017-3451-1; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC5686264/; PubMed
The journal: https://conductscience.org/library/journal-index/7806519; PubMed
Citations, by iCite: 111; iCite
Relative citation ratio, by iCite: 3.81; iCite
Revised in PubMed: 2024-06-04; PubMed

Authors24

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	van den Bent M	Martin
2	Gan HK	Hui K
3	Lassman AB	Andrew B
4	Kumthekar P	Priya
5	Merrell R	Ryan
6	Butowski N	Nicholas
7	Lwin Z	Zarnie
8	Mikkelsen T	Tom
9	Nabors LB	Louis B
10	Papadopoulos KP	Kyriakos P

1 to 10 of 24Source PubMed

See all 24 authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antibodies, Monoclonal, Humanized	Major topic
Glioblastoma	Major topic
Immunoconjugates	Major topic
Adult
Aged
Aged, 80 and over
ErbB Receptors
Female
Humans
Male
Middle Aged

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	25,304,271	CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.	Neuro Oncol	2014	https://conductscience.org/library/papers/25304271	PubMed
2	26,830,009	Therapeutic options in recurrent glioblastoma--An update.	Crit Rev Oncol Hematol	2016	https://conductscience.org/library/papers/26830009	PubMed
3	20,680,104	Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.	Curr Oncol	2010	https://conductscience.org/library/papers/20680104	PubMed
4	29,077,941	Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.	Neuro Oncol	2018	https://conductscience.org/library/papers/29077941	PubMed
5	23,777,544	The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.	FEBS J	2013	https://conductscience.org/library/papers/23777544	PubMed
6	24,335,699	Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.	Neuro Oncol	2014	https://conductscience.org/library/papers/24335699	PubMed
7	20,150,372	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.	Neuro Oncol	2010	https://conductscience.org/library/papers/20150372	PubMed
8	19,269,895	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.	Lancet Oncol	2009	https://conductscience.org/library/papers/19269895	PubMed
9	25,688,333	Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma.	Front Oncol	2015	https://conductscience.org/library/papers/25688333	PubMed
10	18,356,283	Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.	Neuro Oncol	2008	https://conductscience.org/library/papers/18356283	PubMed

1 to 10 of 28

See all 28 references

Cited by88

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 111 citations.

PMID	Title	Journal	Year	In Papers	Source
42,930,186	Translational Challenges and Strategies for Antibody Therapeutics in Glioblastoma.	Curr Oncol	2026	https://conductscience.org/library/papers/42930186	PubMed
42,811,304	Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma.	BMC Cancer	2026	https://conductscience.org/library/papers/42811304	PubMed
42,361,362	Ocular Surface Toxicity of Antibody-Drug Conjugates: Pathogenesis, Diagnosis, Grading, and Treatment of Ocular Adverse Effects.	Cornea	2026	https://conductscience.org/library/papers/42361362	PubMed
42,283,227	Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.	CNS Oncol	2026	https://conductscience.org/library/papers/42283227	PubMed
42,180,101	Antibody-drug conjugates for primary brain tumors.	Front Oncol	2026	https://conductscience.org/library/papers/42180101	PubMed
41,825,107	Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors.	Neoplasia	2026	https://conductscience.org/library/papers/41825107	PubMed
41,768,137	Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology.	Front Bioeng Biotechnol	2026	https://conductscience.org/library/papers/41768137	PubMed
41,503,214	Spatial single-cell profiling identifies protein kinase Cδ-expressing microglia with anti-tumor function in glioblastoma.	iScience	2026	https://conductscience.org/library/papers/41503214	PubMed
41,463,156	A Theoretical Framework for Ligand-Functionalised Magnetic Lipid Nanoparticles in Glioblastoma Therapy.	Cancers (Basel)	2025	https://conductscience.org/library/papers/41463156	PubMed
41,180,763	Safety and efficacy of depatuxizumab mafodotin monotherapy or in combination with temozolomide in patients with/without EGFR-amplified recurrent glioblastoma: a systematic review.	Ann Med Surg (Lond)	2025	https://conductscience.org/library/papers/41180763	PubMed

1 to 10 of 88

See all 88 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
EGFR	1,956	PubTator's text mining	https://conductscience.org/library/genes/1956	NCBI Gene
MGMT	4,255	PubTator's text mining	https://conductscience.org/library/genes/4255	NCBI Gene
TXK	7,294	PubTator's text mining	https://conductscience.org/library/genes/7294	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29075855

GET https://conductscience.org/api/papers/v1/29075855/authors?page=2

API reference For AI assistants